Nature has a fascinating piece today about insider trading in clinical trials. Apparently people are using the information gleaned from participating in said trials to cue their stock trading.
Patients in clinical trials might be using information about the drug they are taking to trade illegally in pharmaceutical stocks, warns a group of doctors and bioethicists. But they have no idea how prevalent the problem might be.
Paul Helft of Indiana University’s School of Medicine, Indianapolis, and his colleagues were alerted to the issue when an increasing number of research subjects in their preliminary clinical trials of cancer drugs said they were buying stock in the company.